Tripos Discovery Research Enters Agreement with CombinatoRx to Optimize Novel Compounds
News Aug 29, 2007
Tripos Discovery Research Limited (TDR), a wholly owned subsidiary of Commonwealth Biotechnologies, Inc. has announced that it has entered into a service agreement with CombinatoRx, Incorporated (CombinatoRx).
Using its combination “High Throughput Screening” technology, cHTS™, CombinatoRx has identified synergistic combinations with utility in key indications which TDR will optimize utilizing its expertise in computational and medicinal chemistry and partner ADME services.
Dr. Mark Warne, Managing Director of TDR, stated, “We are delighted to be entering into this new and exciting agreement with CombinatoRx. Following TDR’s recent acquisition by CBI, this agreement serves as further confirmation that we remain focused on providing integrated drug discovery services to the pharmaceutical and biotech community, working closely with our clients throughout the drug discovery process.”
Stereochemistry is a science of reflection. Two chemical molecules with the same composition and structure, but with one as the mirror image of the other, can produce wildly varying effects. But University of Utah chemist Matt Sigman has been developing a way to get a better grasp on this tricky field of chemistry.READ MORE